{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:50:54Z","timestamp":1746085854433,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["18-184075"],"award-info":[{"award-number":["18-184075"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00023736"],"award-info":[{"award-number":["00023736"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41375-021-01226-0","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T08:03:08Z","timestamp":1616745788000},"page":"2419-2423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells"],"prefix":"10.1038","volume":"35","author":[{"given":"Vaclava","family":"Polivkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Zizkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Koblihova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Curik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliska","family":"Motlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-3247","authenticated-orcid":false,"given":"Cyril","family":"Salek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-5555","authenticated-orcid":false,"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:1634\u201348.","journal-title":"Blood"},{"key":"1226_CR2","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","volume":"141","author":"K Machova Polakova","year":"2015","unstructured":"Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141:887\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol. 2019;12:131.","journal-title":"J Hematol Oncol"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428\u201342.","journal-title":"Cancer Cell"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejca.2013.11.030","volume":"50","author":"R Kastner","year":"2014","unstructured":"Kastner R, Zopf A, Preuner S, Pr\u00f6ll J, Niklas N, Foskett P, et al. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur J Cancer. 2014;50:793\u2013800.","journal-title":"Eur J Cancer"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"21982","DOI":"10.18632\/oncotarget.8010","volume":"7","author":"S Soverini","year":"2016","unstructured":"Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, et al. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016;7:21982\u201390.","journal-title":"Oncotarget"},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.exphem.2009.10.003","volume":"38","author":"KM Polakova","year":"2010","unstructured":"Polakova KM, Polivkova V, Rulcova J, Klamova H, Jurcek T, Dvorakova D, et al. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol. 2010;38:20\u20136.","journal-title":"Exp Hematol"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41375-020-0882-1","volume":"34","author":"K Machova Polakova","year":"2020","unstructured":"Machova Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, et al. Analysis of chronic myeloid leukemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. 2020;34:2113\u20132124.","journal-title":"Leukemia"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. C Am J Hematol. 2012;87:E125\u20138.","journal-title":"C Am J Hematol"},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","volume":"26","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012;26:1475\u201381.","journal-title":"Leukemia"},{"key":"1226_CR11","first-page":"1779","volume":"32","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T. T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res. 2012;32:1779\u201383.","journal-title":"Anticancer Res"},{"key":"1226_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela J, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2020.01.001","volume":"81","author":"Y Akahoshi","year":"2020","unstructured":"Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, et al. Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era. Exp Hematol. 2020;81:60\u20137.","journal-title":"Exp Hematol"},{"key":"1226_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u2013984.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01226-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:42:09Z","timestamp":1684618929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01226-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01226-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KMP and CS\u2014consultancy for Incyte and Angelini.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committees of the Institute of Hematology and Blood Transfusion, Prague. All patients provided written informed consent for the use of their samples for this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}